Barclays
DFTX

Barclays’s Definium Therapeutics DFTX Stock Holding History

Barclays’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.24M Buy
+68,900
New +$1.7M ﹤0.01% 2080

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Barclays's DFTX Position: Q2 2026 in Review

Barclays increased its Definium Therapeutics (DFTX) stake by 27% in Q2 2026, buying an estimated $262K and bringing the position to 50,296 shares worth $2.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2247.

Barclays first reported a position in DFTX in Q1 2022 and has held it in 18 quarters since. The position peaked at $2.46M in Q4 2025. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Barclays held 50,296 shares of Definium Therapeutics worth $2.37M as of Q2 2026.
  • Barclays bought 10,613 Definium Therapeutics shares in Q2 2026, an estimated $262K.
  • Definium Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2247 holding.
  • Barclays first reported a position in Definium Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Definium Therapeutics position peaked at $2.46M in Q4 2025.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.